IPX NASDAQ Week ended 07 Aug 2026

Weekly Investor Report

IperionX Limited American Depositary Share · Basic Materials · Other Industrial Metals & Mining

Open interactive chart View report data
Latest close 25.09 USD
20.9% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -27.9% below the Trend Line and sits at 12.1% of its 52-week range. The latest completed week returned 20.9%, after a 0.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 43/100 conviction, while the latest news-sentiment score is 55/100. Near-term considerations: volume confirmation is below normal; earnings are due in 47d.

Setup score 23 out of 100
Latest Close 25.09 USD 7 Aug 2026
1W Return 20.9% latest completed week
4W Return 0.2% short-term follow-through
12W Return -30.7% quarterly tape
Trend Breadth 30.8% 16 of 52 weeks active
Volume Ratio 0.9x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
  • Next-week expectancy is positive at 61.70% based on similar historical setup states.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 20.9% Latest completed week; four-week move 0.2%. Indicator stack 17/0 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 61.70% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Bullish 43/100 conviction; expected move 13.5%. News sentiment 55/100 48 relevant articles in the latest sentiment read. Event risk 47d Next report is scheduled for 29 Sep 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -27.9% below the Trend Line and sits at 12.1% of its 52-week range. The latest completed week returned 20.9%, after a 0.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0812-week average 0.12

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.08Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 0.2% over four weeks, -30.7% over 12 weeks, and -33.4% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W20.9%
4W0.2%
12W-30.7%
26W-41.8%
52W-33.4%
Active trend streak0 weeks
Active weeks in one year16
Trend breadth30.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.77Latest activity-pressure read.
Pressure change-539.4%Four-week change in activity pressure.
Leadership-42.62Latest relative-leadership reading.
RS change6.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 64% Model confidence 60%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength57/100Blend of value, momentum, and quality. Underlying universe rank 44; rank 1 is best.
Value53/100Relative valuation strength. Underlying universe rank 48; rank 1 is best.
Quality50/100Profitability and accounting quality. Underlying universe rank 51; rank 1 is best.
Momentum53/100Medium-term price momentum. Underlying universe rank 48; rank 1 is best.
Growth53/100Revenue and earnings growth. Underlying universe rank 48; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
0.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-62.9%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.6x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

IPX shows bullish options pressure with a 43/100 conviction score, put-call volume ratio of 0.23, expected move of 13.5%, and Sharemaestro trend signal inactive.

Conviction43/100
Expected move13.5%
Put/call volume0.23
Pressure74
Speculation9
Volatility96
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment55/100

Weighted news tone is neutral across 48 relevant articles.

17 positive · 26 neutral · 5 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings47dNext report is scheduled for 29 Sep 2026; event risk rises as the date approaches.
Options expected move13.5%Nearest-chain priced movement where available.
52-week drawdown-59.2%Distance below the 52-week high.
13-week volatility11.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+23.2%Week of 8 May.
Worst week-33.2%Week of 20 Mar.
Latest week+20.9%Week of 7 Aug.

Shape of recent returns

Strong gains8
Modest gains4
Flat weeks0
Modest losses3
Sharp losses11
Recent vol11.0%13-week weekly-return volatility.
Base vol12.9%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew10.8% / -10.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape22/100

Trend, activity pressure, participation, and risk combine to a 22/100 tape read.

 Indicator analysis19/100

Latest 12-week confirmation: trend 0/12, activity pressure 5/12, relative leadership 0/12.

Activity pressure 0.08; No reversal markers Next-Week ExpectancyPositive 61.70%

Next-week expectancy is positive with a 61.70% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors52/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 48; Small Cap Core rank 52 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options43/100

IPX shows bullish options pressure with a 43/100 conviction score, put-call volume ratio of 0.23, expected move of 13.5%, and Sharemaestro trend signal inactive.

Bullish · Call-side pressure · Expected move 13.5% Sentiment55/100

Weighted news tone is neutral across 48 relevant articles.

Iperionx Limited Issues Restricted Stock Units and Incentive Options Under Employee Incentive Scheme Insiders50/100

No recent insider transaction evidence is stored.

 Earnings47d

Next report is scheduled for 29 Sep 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 202625.09 USD20.9%34.80 USD24.97 USD-0.77-42.621.2MOff
31 Jul 202620.75 USD-3.8%35.42 USD24.85 USD-0.54-50.621.3MOff
24 Jul 202621.56 USD-6.0%36.06 USD24.76 USD-0.32-49.021.6MOff
17 Jul 202622.94 USD-8.3%36.57 USD24.67 USD-0.07-47.281.6MOff
10 Jul 202625.03 USD-13.0%36.91 USD24.57 USD0.17-45.332.0MOff
3 Jul 202628.78 USD8.6%37.27 USD24.46 USD0.17-36.491.1MOff
26 Jun 202626.50 USD-14.6%37.44 USD24.33 USD0.14-41.261.5MOff
19 Jun 202631.03 USD-13.9%37.68 USD24.20 USD0.11-34.682.4MOff
12 Jun 202636.05 USD2.4%37.62 USD24.05 USD-0.03-22.34996.2KOff
5 Jun 202635.22 USD-14.8%37.55 USD23.87 USD-0.04-22.361.1MOff
29 May 202641.36 USD9.9%37.60 USD23.69 USD0.02-13.01780.5KOff
22 May 202637.62 USD4.0%37.68 USD23.46 USD-0.20-18.361.1MOff
15 May 202636.19 USD-12.2%38.08 USD23.26 USD-0.43-20.371.7MOff
8 May 202641.21 USD23.2%38.58 USD23.07 USD-0.62-9.342.0MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context